Ko Ja (Cayman) Co., Ltd. (TPE:5215)

Verve Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,035	885.05	914.41	1,100	844.04	762.52
Short-Term Investments	256.48	341.41	187.1	355.96	575.01	148.11
Trading Asset Securities	97.64	89.4	98.2	53.72	44.06	26.65
Cash & Short-Term Investments	1,389	1,316	1,200	1,510	1,463	937.28
Cash Growth	-8.86%	9.68%	-20.56%	3.22%	56.10%	17.28%
Accounts Receivable	965.01	1,090	1,039	807.01	1,328	1,648
Other Receivables	74.7	87.11	31.8	9.27	2.41	0.08
Receivables	1,040	1,177	1,071	816.28	1,331	1,648
Inventory	498.17	425.59	315.86	367.37	328.49	333.64
Prepaid Expenses	-	74.97	23.13	55.39	89.97	51.22
Other Current Assets	5.44	5.93	1.57	3.14	379.22	3
Total Current Assets	2,933	2,999	2,611	2,752	3,592	2,973
Property, Plant & Equipment	1,120	1,077	1,109	1,157	923.63	656.18
Long-Term Investments	430.63	425.26	432.48	429.22	60.32	58.86
Goodwill	68.55	67.58	64.29	65.5	-	-
Other Intangible Assets	93.42	95.52	71.05	121.7	45.02	52.6
Long-Term Deferred Tax Assets	11.3	10.79	28.98	29.78	35.52	35.97
Other Long-Term Assets	96.22	87.89	29.19	48.82	18.18	132.75
Total Assets	4,753	4,763	4,346	4,604	4,674	3,910
Accounts Payable	130.08	191.24	183.33	100.51	213.92	278.92
Accrued Expenses	337.61	352.78	320.18	310.9	426.99	442.45
Short-Term Debt	81.26	103.42	43.39	253.88	249.12	-
Current Portion of Leases	13.41	12.45	11.84	8.66	-	10.54
Current Income Taxes Payable	17.4	25.06	33.66	65.74	34.98	73.4
Current Unearned Revenue	2.47	0.88	0.67	0.7	10.39	0.57
Other Current Liabilities	297.94	118.72	83.37	185.84	134.36	90.54
Total Current Liabilities	880.16	804.55	676.45	926.21	1,070	896.42
Long-Term Leases	11.59	14.8	19.81	25.05	-	21.73
Long-Term Unearned Revenue	-	-	-	-	31.29	-
Long-Term Deferred Tax Liabilities	204.57	199.25	195.87	203.42	207.32	173.88
Other Long-Term Liabilities	2.9	2.08	2.35	2.02	2.85	2.39
Total Liabilities	1,099	1,021	894.47	1,157	1,311	1,094
Common Stock	643.38	643.38	643.38	643.38	643.38	593.38
Additional Paid-In Capital	1,532	1,490	1,490	1,490	1,494	1,013
Retained Earnings	1,324	1,454	1,313	1,265	1,322	1,283
Comprehensive Income & Other	63.05	23.47	-121.81	-73.82	-134.91	-118.36
Total Common Equity	3,562	3,612	3,325	3,325	3,324	2,772
Minority Interest	92.02	130.4	127.45	122.51	38.7	43.44
Shareholders' Equity	3,654	3,742	3,452	3,447	3,363	2,815
Total Liabilities & Equity	4,753	4,763	4,346	4,604	4,674	3,910
Total Debt	106.26	130.67	75.04	287.59	249.12	32.27
Net Cash (Debt)	1,283	1,185	1,125	1,223	1,214	905.01
Net Cash Growth	-1.26%	5.38%	-8.01%	0.71%	34.14%	15.54%
Net Cash Per Share	19.72	18.24	17.37	18.85	19.04	15.73
Filing Date Shares Outstanding	64.34	64.34	64.34	64.34	64.34	59.34
Total Common Shares Outstanding	64.34	64.34	64.34	64.34	64.34	59.34
Working Capital	2,053	2,195	1,935	1,826	2,522	2,077
Book Value Per Share	55.37	56.13	51.67	51.68	51.67	46.71
Tangible Book Value	3,400	3,448	3,189	3,137	3,279	2,719
Tangible Book Value Per Share	52.85	53.60	49.57	48.77	50.97	45.82
Land	207.81	207.23	211.67	211.67	83.77	83.77
Buildings	625.78	706.75	675.09	682.13	550.48	407.21
Machinery	1,075	1,007	1,004	978.77	886.64	712.08
Construction In Progress	-	-	8.9	-	0.56	1.6
Leasehold Improvements	5.45	50.59	44.35	45.18	43.95	44.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.